GlobalData report, "Hepatitis B - Analysis of Drug pipelines and market forecasts to 2016" is an essential source of information and analysis of hepatitis B in the global market. The report identifies key trends that define and drive the world market for hepatitis B. This report also provides information on the prevalent competitive landscape and emerging players are expected to make a significant change in the market position of existing market leaders. Most importantly, this report provides valuable information about the product portfolio in the global hepatitis B (Hep B).
GlobalData analysis reveals that the market is growing at a compound annual growth rate (CAGR) of 5.9% since 2001 to reach $ 879m in 2009. The hepatitis B market growth will be driven by a growing number of patients in the coming years. The hepatitis B market is currently dominated by antiviral therapy and this trend will continue, without innovative molecules under development. GlobalData analysis showed that hepatitis B tube is weak in terms of number of molecules. The molecules of the hepatitis B pipe on the market consists mainly of me-too molecules (five), and combination therapy (five), with efficacy and safety profile similar to the current therapeutic options. The molecules of the most promising among them is the combination of adefovir and entecavir emtricitabine plus tenofovir more.
This report builds on data and information from proprietary databases, primary and secondary research and analysis of the home team GlobalData of industry experts.
Scope
The scope of this report are:
Hep B data annualized total market revenues 2001 to 2009, forecast forward for seven years until 2016.
Geographies covered by this report include the U.S. (United States), English (UK), Italy, Spain, Germany, France and Japan.
Tube data analysis provides an overview of the different phases, mechanisms of action are being developed and emerging trends. Fundamental mechanism of class action is a nucleoside / nucleotide antivirals, glucocorticoid and T Natural murderer (NKTs).
Analysis of market competition in the current and future global market for hepatitis B. The main market players are covered Bristol-Myers Squibb and Gilead Science Inc.
Insightful review of the industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of the implications.
Key topics covered include the evaluation of strategic competition, market characterization, unmet needs and the implications for future market associated with hepatitis B.
Reasons to buy
This report will improve their decision-making in a way that is faster and time sensitive. This allows you to:
Design and development of its strategy of acquiring licenses and licensing, by reviewing products and developing technologies, and by identifying companies with the most robust pipeline.
Develop business strategies by understanding the trends set the pace in the world market for hepatitis B.
The revenue of the unit by understanding key trends, products and technologies, market segments and companies of hepatitis B have an impact on the global market in the future.
Formulate effective sales strategies and marketing by understanding the competitive environment and analyzing the results of various competitors.
Identify emerging players with strong potential product portfolio and create a counter-strategy to gain competitive advantage.
Organize your marketing and sales efforts by identifying the categories and market segments that present greater opportunities for the consolidation of investments and strategic alliances.
What is the next big thing in hepatitis B of the global landscape? - Identify, understand and use.
GlobalData analysis reveals that the market is growing at a compound annual growth rate (CAGR) of 5.9% since 2001 to reach $ 879m in 2009. The hepatitis B market growth will be driven by a growing number of patients in the coming years. The hepatitis B market is currently dominated by antiviral therapy and this trend will continue, without innovative molecules under development. GlobalData analysis showed that hepatitis B tube is weak in terms of number of molecules. The molecules of the hepatitis B pipe on the market consists mainly of me-too molecules (five), and combination therapy (five), with efficacy and safety profile similar to the current therapeutic options. The molecules of the most promising among them is the combination of adefovir and entecavir emtricitabine plus tenofovir more.
This report builds on data and information from proprietary databases, primary and secondary research and analysis of the home team GlobalData of industry experts.
Scope
The scope of this report are:
Hep B data annualized total market revenues 2001 to 2009, forecast forward for seven years until 2016.
Geographies covered by this report include the U.S. (United States), English (UK), Italy, Spain, Germany, France and Japan.
Tube data analysis provides an overview of the different phases, mechanisms of action are being developed and emerging trends. Fundamental mechanism of class action is a nucleoside / nucleotide antivirals, glucocorticoid and T Natural murderer (NKTs).
Analysis of market competition in the current and future global market for hepatitis B. The main market players are covered Bristol-Myers Squibb and Gilead Science Inc.
Insightful review of the industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of the implications.
Key topics covered include the evaluation of strategic competition, market characterization, unmet needs and the implications for future market associated with hepatitis B.
Reasons to buy
This report will improve their decision-making in a way that is faster and time sensitive. This allows you to:
Design and development of its strategy of acquiring licenses and licensing, by reviewing products and developing technologies, and by identifying companies with the most robust pipeline.
Develop business strategies by understanding the trends set the pace in the world market for hepatitis B.
The revenue of the unit by understanding key trends, products and technologies, market segments and companies of hepatitis B have an impact on the global market in the future.
Formulate effective sales strategies and marketing by understanding the competitive environment and analyzing the results of various competitors.
Identify emerging players with strong potential product portfolio and create a counter-strategy to gain competitive advantage.
Organize your marketing and sales efforts by identifying the categories and market segments that present greater opportunities for the consolidation of investments and strategic alliances.
What is the next big thing in hepatitis B of the global landscape? - Identify, understand and use.
No comments:
Post a Comment